Tamura Tomohide | Division Of Internal Medicine National Cancer Center Hospital

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Genetic Variations and Haplotypes of ABCC2 Encoding MRP2 in a Japanese Population
日本人におけるGSTT1及びGSTM1の遺伝子多型の同定及びハプロタイプ構造の解析
Genetic Variations of VDR/NR1I1 Encoding Vitamin D Receptor in a Japanese Population
Genetic Variations and Frequencies of Major Haplotypes in SLCO1B1 Encoding the Transporter OATP1B1 in Japanese Subjects : SLCO1B1^*17 is More Prevalent Than ^*15
Genetic Variation and Haplotype Structure of the ABC Transporter Gene ABCG2 in a Japanese Population
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days
Twenty-six Novel Single Nucleotide Polymorphisms and their Frequencies of the NR113 (CAR) Gene in a Japanese Population
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models
Reversal of Cisplatin Resistance by the 1,4-Benzothiazepine Derivative, JTV-519
CPT-11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors
The role of a common TNNT2 polymorphism in cardiac hypertrophy
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity
What is the most informative pharmacodynamic model for paclitaxel (T)? : a 3 hour-infusion vs. 24-hour infusion.
Problems with Registration-Directed Clinical Trials for Lung Cancer in Japan
Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
Tumor response to chemotherapy : The validity and reproducibility of RECIST guidelines in NSCLC patients
INHIBITORY EFFECTS OF REPEATED INTRAVENOUS INJECTIONS OF DEXAMETHASONE ON PULMONARY TOXICITY OF A NEW MITOMYCIN C ANALOGUE, KW-2149, IN A NOVEL RAT MODEL
Inhibitory effects of dexamethasone on pulmonary toxicity of a new mitomycin C analogue KW-2149 in a novel rat model.
Prospective Evaluation of the Feasibility of Cisplatin-based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
Absence of Tumor Promoting Activity of Xylazine in a Two-stage Nasal Carcinogenesis Model in N-bis(2-hydroxypropyl)nitrosamine-treated Rats
Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)
Phase I Study of Paclitaxel by Three-hour Infusion : Hypotension Just after Infusion Is One of the Major Dose-limiting Toxicities
MECHANISM OF FK506-INDUCED GLUCOSE INTOLERANCE IN RATS
Genetic Polymorphisms of Copper- and Platinum Drug-efflux Transporters ATP7A and ATP7B in Japanese Cancer Patients
Translational and clinical studies of target-based cancer therapy
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
P7-07 Is emulsification of the test substance with Freund's complete adjuvant(FCA) necessary in the guinea pig maximization test?(IMMUNE AND ALLERGIC SYSTEM/KIDNEYS AND URINARY EXCRETION SYSTEM/CYTOTOXICITY/OTHERS-1)(GENERAL SESSION BY POSTER PRESENTATION
EFFECTS OF pH AND OSMOLALITY ON PHLEBITIC POTENTIAL OF INFUSION SOLUTIONS FOR PERIPHERAL PARENTERAL NUTRITION
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
A Pharmacokinetic and Pharmacodynamic Analysis of CPT-11 and Its Active Metabolite SN-38
"P-1 Effects of pH and Osmolality on Phlebitic Potential of infusion Solutions for Peripheral Parenteral Nutrition.
Innovator and generic cisplatin formulations : Comparison of renal toxicity

もっと見る

スポンサーリンク